anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Veterans randomized to the SDTP will be paired with an experienced Warrior Canine Connection (WCC) Mission Based Trauma Recovery (MBTR)-Trainer (MBRT-T) and a service dog (SD). One hour training modules will be scheduled once a week for 8 weeks. Participants will come to WCC for all the weekly training modules. Participants will be paired with the same SD for the duration of the SDTP unless an unforeseen circumstance arises and the SD needs to be removed from the SDTP. The MBTR-T will deliver the prescribed SDTP modules created by WCC. Each session will be fully supervised by a WCC MBTR-T to address any concerns or safety issues that may arise.
FIELD: organic chemistry. SUBSTANCE: composition for antitumor therapy is prepared by dissolving alkylphosphocholine of the general formula (I)   in a mixture of alkylglycerol ester of the general formula (II)   with water and addition of citrate solution as a buffer to pH 4.0-6.0. Obtained composition is stable without addition of preserving agents and antioxidants. Composition is used in medicine, in part, oncology. EFFECT: improved method of preparing. 5 cl, 5 tbl
After the pre-tests were completed, the pregnant women were divided into experimental and control groups. Within the scope of the Transition to Motherhood Program, 5-session training and phone follow-ups were made in the first week and the fourth week postpartum to the experimental group. Post-tests were applied to the experimental group at the postpartum 1st month and 4th month.
Tenofovir disoproxil fumarate (TDF) seems to prevent hepatocellular carcinoma (HCC) in patients with chronic hepatitis B virus (HBV). However, the mechanism is still little known. This study aimed to investigate the the roles and mechanisms of TDF, tenofovir alafenamide fumarate (TAF), and entecavir (ETV) on the malignant characteristics of liver cancer cells. Using the wound-healing assays, transwell assays, matrigel transwell assays, and cell counting kit-8 (CCK-8) assays, it was possible to identify that TDF/TAF, inhibited migration, invasion, and proliferation of HepG2 cells and Huh7 cells. To investigate the mechanisms, we performed TOP/FOP-Flash system, Western blot, and RT-qPCR assays of liver cancer cells cultured with TDF/TAF and found a lower activity of Wnt/β-catenin signaling pathway compared with control cells. Finally, Hepatitis C virus p7 trans-regulated protein 3 (p7TP3), a tumor suppressor in liver cancers, was significantly increased in HepG2 cells and Huh7 cells that treated with TDF/TAF. However, entecavir (ETV)-treated liver cancer cells showed no significant difference in the malignant characteristics of liver cancer cells, activity of Wnt/β-catenin signaling pathway, and expression of p7TP3, compared with the control groups. To conclude, TDF/TAF maybe novel promising therapeutic strategy for liver cancers, including HCC and hepatoblastoma, via Wnt/β-catenin signaling pathway, by up-regulating expression of the tumor suppressor, p7TP3.
Transmetatarsal amputation (TMA) is a common surgical procedure for addressing severe forefoot pathologies, such as peripheral vascular disease and diabetic foot infections. Variability in research methodologies and findings within the existing literature has hindered a comprehensive understanding of healing rates and complications following TMA. This meta-analysis and systematic review aims to consolidate available evidence, synthesising data from multiple studies to assess healing rates and complications associated with closed TMA procedures. Following Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) guidelines, a systematic search of Medline, Embase, and Cochrane databases was conducted for articles published from January 1st, 1988, to June 1st, 2023. Inclusion criteria comprised studies reporting healing rates in non-traumatic transmetatarsal amputation patients with more than 10 participants, excluding open TMAs. Two independent reviewers selected relevant studies, with disagreements resolved through discussion. Data extracted from eligible studies included patient demographics, healing rates, complications, and study quality. Among 22 studies encompassing 1569 transmetatarsal amputations, the pooled healing rate was 67.3%. Major amputation rates ranged from 0% to 55.6%, with a random-effects pooled rate of 23.9%. Revision rates varied from 0% to 36.4%, resulting in a pooled rate of 14.8%. 30-day mortality ranged from 0% to 9%, with a fixed-effects pooled rate of 2.6%. Post-operative infection rates ranged from 3.0% to 30.7%, yielding a random-effects pooled rate of 16.7%. Dehiscence rates ranged from 1.7% to 60.0%, resulting in a random-effects pooled rate of 28.8%. Future studies should aim for standardised reporting and assess the physiological and treatment factors influencing healing and complications.
Immune thrombocytopenia (ITP) is an acquired blood disease in which the individual's immune system destroys platelets, the blood cells responsible for clotting. A number of standard treatments exist to decrease the destruction of platelets, including drugs such as the steroid hormone prednisone, or removal of the spleen. Over a third of adult patients will not maintain adequate platelet counts with these treatments. Alternative treatments may be indicated due to bleeding symptoms or baseline platelet counts less than 20,000/ul, a level at which spontaneous serious bleeding can occur. Therapy for chronic ITP is generally effective in less than 30-50% of patients, however, and most of these agents have significant toxicities with long-term use, are expensive, or their administration interferes with daily activities.

Daclizumab is a humanized anti-interleukin-2 receptor monoclonal antibody that works by targeting and impairing activated T lymphocytes, a subset of white blood cells that has been thought to be involved in the development and maintenance of ITP. Daclizumab is a well-tolerated and time-limited therapy, and is easily administered on an outpatient basis. The purpose of this study is to test the efficacy of daclizumab as either a sole agent in the treatment of chronic, symptomatic ITP, or as a treatment that might allow a decrease or discontinuation of medications such as prednisone.
PURPOSE: An injection composition containing hydroxychloroquine for local administration to treat cancer is provided to ensure cytotoxicity in vitro. CONSTITUTION: An injection composition for topical administration to treat cancer contains hydroxychloroquine or salt thereof. The composition is directly injected to the cancer cells. The salt of hydroxychloroquine is sulphate. The content of hydroxychloroquine is 5-25%(w/v). The composition additionally contains 1-2%(w/v) of lidocaine as a local anesthetic and 0.1-0.5%(w/v) of riboflavin as an antioxidant.
PURPOSE:To obtain a smoke generating agent for treating hemorrhoid consisting of moxa capable of generating combustion smoke for treating hemorrhoid by it's combustion, capable of preventing congestion of vein resulted in hemorrhoid and effective in healing of affected part of hemorrhoid without causing side effects. CONSTITUTION:The aimed agent containing moxa capable of generating combustion smoke for treating hemorrhoid by it's combustion as a main ingredient. A moxa obtained by drying leaf of Artemisia indica which is a perennial grass of Artemisia and then making the dried leaf linear is used as the moxa. Hemorrhoid is treated by exposing affected part into combustion smoke obtained by burning moxa. The agent can be also applied by rubbing ash after combustion into the affected part. The affected part is nearly completely healed by repeatedly using moxa at an amount of 10g in combustion time of about 15-20min once daily for about 8 day.
Preeclampsia (PE) poses a considerable risk to the long-term cardiovascular health of both mothers and their offspring due to a hypoxic environment in the placenta leading to reduced fetal oxygen supply. Cholesterol is vital for fetal development by influencing placental function. Recent findings suggest an association between hypoxia, disturbed cholesterol homeostasis, and PE. This study investigates the influence of hypoxia on placental cholesterol homeostasis. Using primary human trophoblast cells and placentae from women with PE, various aspects of cholesterol homeostasis were examined under hypoxic and hypoxia/reoxygenation (H/R) conditions. Under hypoxia and H/R, intracellular total and non-esterified cholesterol levels were significantly increased. This coincided with an upregulation of HMG-CoA-reductase and HMG-CoA-synthase (key genes regulating cholesterol biosynthesis), and a decrease in acetyl-CoA-acetyltransferase-1 (ACAT1), which mediates cholesterol esterification. Hypoxia and H/R also increased the intracellular levels of reactive oxygen species and elevated the expression of hypoxia-inducible factor (HIF)-2α and sterol-regulatory-element-binding-protein (SREBP) transcription factors. Additionally, exposure of trophoblasts to hypoxia and H/R resulted in enhanced cholesterol efflux to maternal and fetal serum. This was accompanied by an increased expression of proteins involved in cholesterol transport such as the scavenger receptor class B type I (SR-BI) and the ATP-binding cassette transporter G1 (ABCG1). Despite these metabolic alterations, mitogen-activated-protein-kinase (MAPK) signaling, a key regulator of cholesterol homeostasis, was largely unaffected. Our findings indicate dysregulation of cholesterol homeostasis at multiple metabolic points in both the trophoblast hypoxia model and placentae from women with PE. The increased cholesterol efflux and intracellular accumulation of non-esterified cholesterol may have critical implications for both the mother and the fetus during pregnancy, potentially contributing to an elevated cardiovascular risk later in life.
To study the role of gut health, more specifically the intestinal barrier, in individuals with psoriasis and the effects of fasting on both organs in a prospective cohort cross-over study. The investigators will test whether MIF can improve (i) skin lesions (clinical and molecular level), (ii) intestinal integrity markers such as zonulin, IFABP and sCD14, and (iii) the timing of these improvements. As such, it can be determined whether fasting benefits psoriasis and gut health. MIF will consist of a limited calorie uptake of 500 kcal for 2 days a week. The remaining days of the week are as usual. Gut and skin health will be tested at the molecular level during 12 weeks with another crossover of 12 weeks (alternating between MIF and usual diet).
Reports of necrotizing fasciitis of the perineum (Fournier's gangrene), a rare but serious and life-threatening necrotizing infection requiring urgent surgical intervention, have been identified in patients with diabetes mellitus receiving SGLT2 inhibitors, including empagliflozin. Cases have been reported in both females and males. Serious outcomes have included hospitalization, multiple surgeries, and death.

Patients treated with SYNJARDY or SYNJARDY XR presenting with pain or tenderness, erythema, or swelling in the genital or perineal area, along with fever or malaise, should be assessed for necrotizing fasciitis. If suspected, start treatment immediately with broad-spectrum antibiotics and, if necessary, surgical debridement. Discontinue SYNJARDY or SYNJARDY XR, closely monitor blood glucose levels, and provide appropriate alternative therapy for glycemic control.
PURPOSE: A composition containing a compound of chemical formula 1 for preventing or treating hepatitis type B is provided to ensure strong antiviral activity and safety. CONSTITUTION: A composition for suppressing binding between hepatitis B virus and a virus receptor contains a compound of chemical formula 1 or salt thereof as an active ingredient. The compound is isolated from Hovenia dulcis Thunb fruit extract or fraction thereof. The Hovenia dulcis Thunb fruit extract is isolated using water, n-hexane, chloroform, ethyl acetate, n-butanol, or mixture thereof. The fraction is prepared using water, methanol, chloroform, ethyl acetate, or mixture thereof. The composition is a pharmaceutical composition or food composition.
Cesarean deliveries are the most common surgical procedure performed in the United States, and scheduled cesarean deliveries account for at least 40% of all cesarean deliveries every year. A significant decrease in cesarean delivery associated maternal morbidity has been achieved with preoperative prophylactic single-dose cephalosporin given within 60 minutes of skin incision. Also, on laboring patients and/or with rupture of membranes, several studies suggest that adding azithromycin to standard cephalosporin prophylaxis is not only cost-effective but reduces overall rates of endometritis and wound infection. Azithromycin provides effective coverage against Ureaplasma, commonly associated with increased rates of endometritis. Although two-drug regimen has been suggested for laboring and/or patients that undergo cesarean delivery, no studies have investigated the potential benefits of two-drug regimen in non-laboring patients. No increase in neonatal morbidity was noted with adjunctive azithromycin prophylaxis, including adverse events.
NITROSTAT is contraindicated in patients who are using a selective inhibitor of cyclic guanosine monophosphate (cGMP)-specific phosphodiesterase type 5 (PDE-5). PDE-5-Inhibitors such as avanafil, sildenafil, vardenafil, and tadalafil have been shown to potentiate the hypotensive effects of organic nitrates.

NITROSTAT is contraindicated in patients who are taking soluble guanylate cyclase (sGC) stimulators. Concomitant use can cause hypotension.

The time course and dose dependence of these interactions have not been studied, and use within a few days of one another is not recommended. Appropriate supportive care for the severe hypotension has not been studied, but it seems reasonable to treat this as a nitrate overdose, with elevation of the extremities and with central volume expansion.
The invention provides a compound Chinese-western powder for treating fish disease. The compound Chinese-western powder comprises the following raw materials in part by weight: 15 to 20 parts of acalypha australis, 10 to 15 parts of herba agrimoniae, 9 to 10 parts of rhizoma coptidis, 9 to 10 parts of folium isatidis, 10 to 15 parts of cyrtomium fortunei, 0.005 to 0.01 part of vitamin C, and 0.18 to 0.37 part of transfer factor. The five traditional Chinese herbs in the invention are cooperated tightly and complementarily, and have significant curative effect in smoothly removing viruses of fishes. The western medicines, i.e. vitamin C and the transfer factor, can enhance immunity of fishes, and have remarkable curative effect in treating hemorrhagic disease, enteritis, sepsis and gill rot. The compound Chinese-western powder provided by the invention can be easily absorbed and completely metabolized by fishes, has the advantages of no toxic and side effects, no allergic reaction, no antigenicity, small dosage, quick effect andlong action time, and can solve the problem of abuse and residue of fish-dependent chemical drugs.
PURPOSE:To control infectious diseases of livestock, by using a drug containing polyhexamethylene biguanidine or its salt through spraying, scattering, or washing. CONSTITUTION:0.01-10wt%, preferably 0.03-5wt% solution of a compound shown by the formula (n is polymerization degree corresponding to 700-1,300 molecular weight of the compound ) or its salt (e.g., inorganic salt such as hydrohalide, sulfate, etc. or organic salt such as lactate, tartrate, succinate, etc.) or its fine powder is used by spraying, scattering, or washing, to control infectious diseases of livestock (e.g., swine, chicken, cattle, etc.). Salmonella pullorum, Salmonella typhimurium, pathaogenic Escherichia coli, etc. may be cited as a mold of the cause of the infectious diseases. The active ingredient shows a sterilizing action in 2,000-16,000 times dilution degree by 10-15min sensitization, and sterilizing action on Escherichia coli, etc. will not decrease much even in the presence of fowl droppings.
Many patients suffer from chronic pain despite the absence of injury or sufficient biomedical disease to explain their pain. These pains are highly resistant to treatment. Psychological therapies designed to help patients undermine the negative thought and behavioral patterns that maintain pain provide only modest pain relief, leading to suspicion that such pain might be maintained by unconscious processes. An article in this issue of Psychosomatic Medicine provides the first experimental evidence that unconscious negative memories can increase pain unpleasantness. These findings are exciting, but the effect sizes are small, which is consistent with the small effects of psychological therapy. It seems that pain stubbornly resists psychological manipulation, but this work provides some hope that psychological therapy for pain can be improved to provide more effective pain relief.
Lenalidomide is an analogue of thalidomide with immunomodulatory, antiangiogenic, and antineoplastic properties. Cellular activities of lenalidomide are mediated through its target cereblon, a component of a cullin ring E3 ubiquitin ligase enzyme complex. In vitro, in the presence of drug, substrate proteins (including Aiolos, Ikaros, and CK1α) are targeted for ubiquitination and subsequent degradation leading to direct cytotoxic and immunomodulatory effects. Lenalidomide inhibits proliferation and induces apoptosis of certain hematopoietic tumor cells including MM, mantle cell lymphoma, and del (5q) myelodysplastic syndromes in vitro. Lenalidomide causes a delay in tumor growth in some in vivo nonclinical hematopoietic tumor models including MM. Immunomodulatory properties of lenalidomide include increased number and activation of T cells and natural killer (NK) cells leading to direct and enhanced antibody-dependent cell-mediated cytotoxicity (ADCC) via increased secretion of interleukin-2 and interferon-gamma, increased numbers of NKT cells, and inhibition of pro-inflammatory cytokines (e.g., TNF-α and IL-6) by monocytes. In MM cells, the combination of lenalidomide and dexamethasone synergizes the inhibition of cell proliferation and the induction of apoptosis.
An antimicrobial composition is provided. The composition comprises a chloramid of hyaluronic acid or of modified hyaluronic acid. The chloramid has an amidic group (—NH—CO—). The hydrogens of the amidic group are substituted by chlorine atoms according to the structural formula —NCl—CO—. The composition further comprises an iodide. The substitution degree of the hyaluronic acid or of the modified hyaluronic acid by chlorine is in an amount of from 50% to 100%.
PCT No. PCT/AU95/00261 Sec. 371 Date Feb. 11, 1997 Sec. 102(e) Date Feb. 11, 1997 PCT Filed May 4, 1995 PCT Pub. No. WO95/30436 PCT Pub. Date Nov. 16, 1995The present invention relates generally to adjuvants which comprise a combination of at least two cytokines or functional derivatives thereof. More particularly, the present invention is directed to an adjuvant such as a vaccine adjuvant comprising at least two cytokines or functional derivatives thereof wherein the cytokines are selected from IL-1 beta  and TNF alpha  or IL-1 beta  and GM-CSF. The present invention is farther directed to genetic adjuvants encoding at least two cytokines or derivatives thereof either separately or fused together. The present invention also contemplates a method for enhancing an immune response to an antigen comprising the administration of at least two cytokines which act in synergy to enhance an immune response to said antigen. The present invention is particularly useful in pharmaceutical vaccines and genetic vaccines in humans and livestock animals.
Patients who are in the ICU at the time of enrollment. Patients will receive anti-SARS-CoV-2 convalescent plasma.
PURPOSE:To decompose and decolor melanin using Basidonycetes having melanin decomposing property. CONSTITUTION:Melanin is decomposed and decolored by bringing melanin into contact with a microbial cell of Basidonycetes having melanin decomposing property, its cultured material and/or its treated material in-vivo or in-vitro. The reaction system is kept in a state where nitrogen is limited (under nitrogen source-free conditions or conditions reduced to as small amount of nitrogen as possible) in contact with melamine and combined use of glucose is further effective in this time. As necessary, the reaction system may be incubated at 10-45 deg.C for a required time. When a microorganism cultured in a culture medium previously containing melanin and/or its precursor under conditions where nitrogen is limited, further good result is obtained. The usable microorganism contains wood-destroying fungus having melanin-decomposability, e.g. NK-1148 strain (FERM BP-1859). This microorganism can be utilized for the production of skin-whitening cosmetics for the treatment of stain and ephelis as well as decoloring of melanin-containing industrial products.
Autologous stem cell transplant (ASCT) can lead to a complete or partial disappearance of the myeloma in about 2 out of 3 patients. However, an ASCT only sometimes leads to a cure of the myeloma. In about half the patients the myeloma comes back after about 1-2 years. In about 90% of patients it comes back by about 10 years after transplant.

One possible way to improve upon the results of ASCT for myeloma is to help the body's defense or immune system recover faster after transplant. Another way is to teach the body's immune system to fight against the myeloma cells.

In two earlier research studies which included more than 100 patients, certain types of immune cells called "T cells" or "T lymphocytes" were taken out of a patient's body using a procedure called "apheresis". These cells were then grown up in the lab. After the transplant, these T cells were put back into the patients. The replaced T cells helped the patients'immune systems to recover faster after the transplant. In addition, when the T cells were given back to patients they also received a vaccination. The vaccination or injection was for a certain type of pneumonia germ called "pneumococcus". We found that most patients built up protection against this pneumonia-causing germ. In another study, we used a possible myeloma cancer vaccine. However, we found that less than half the patients responded to this vaccine.

In this new study, we want to test a different type of myeloma cancer vaccine. This different cancer vaccine is based on a protein called MAGE-A3. The MAGE-A3 protein is found in about 50% of cases of myeloma. This vaccine consists of small pieces of protein (called "peptides") which come from the MAGE-A3 protein. In order to help the immune system respond better we will add two new steps. First we will add an immune system stimulant called "Hiltonol®" to each vaccination. Hiltonol® is a chemical substance that turns on several parts of the immune system. It may make the immune system better able to respond to the vaccine. It has been tested in several hundred patients and has been used with about a dozen different types of cancer and germ vaccines. Second, starting about 100 days after the transplant procedure, patients will get a medicine called Lenalidomide. Lenalidomide is already approved by the Food and Drug Administration (FDA) for treatment of myeloma. In this study, we want to know whether Lenalidomide could help to improve the body's ability to respond to the vaccinations and help to treat the myeloma itself.
Experimental group will receive Staphylococcus and Neisseria Tablets (0.3mg/tablet) and standard care. Administration Staphylococcus and Neisseria is 4 tablets each time and 3 times a day, and treatment period ranges from 3 to 6 months.